Forvisirvat
Forvisirvat ( , ; developmental code name SP-624) is a selective sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Forvisirvat ( , ; developmental code name SP-624) is a selective sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia. It is taken by mouth. The drug produces antidepressant-like effects in multiple animal models of depression.
As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.
See also
List of investigational antidepressants List of investigational antipsychotics Griseofulvin
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374839509 under CC BY-SA 4.0; modifications have been made.